Royalty Report: Drugs, Cancer, Therapeutic – Collection: 243413

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Biotechnology
  • Ophthalmological
  • Drug Discovery
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 243413

License Grant
Licensor grants an exclusive, worldwide license to Licensors entire interest in and to Licensed Patents within the Field to make, have made, use, import, have imported, sell, offer for sale and otherwise exploit and distribute Licensed Products, and,  practice any method, process or procedure included within the Licensed Patents; and to have any of the foregoing performed on its behalf by a third party.
License Property
The patents are for Vascular Targeting Agents and targeting vascular endothelial growth factor or VEGF.

The VTA technology is a proprietary therapeutic platform designed to specifically target tumor vasculature and subsequently destroy the tumor with various attached therapeutic agents.

Field of Use
Field shall mean vascular endothelial growth factor (VEGF), in the native, mutants and variants thereof, conjugated to cytotoxic drugs, toxins, radionuclides or photodynamic therapy agents for targeting tumors and cells expressing VEGF receptors and tumor blood vessels for therapy of cancer and blood vessel proliferative disorders, including but not limited to macular degeneration, diabetic retinopathy, and pannus formation.

IPSCIO Record ID: 2250

License Grant
The VTA technology was acquired in April of 1997 through the Licensee's acquisition of the Licensor's Phase I Study.  The Licensee has entered into several license agreements in order to acquire all of the rights which it deems necessary to proceed with its vascular targeting agent ('VTA's') technology.
License Property
VTA’s act by destroying the vasculature of solid tumors.  VTA’s are multifunctional molecules that target the capillaries and blood vessels of solid tumors. Once there, these agents block the flow of oxygen and nutrients to the underlying tissue by creating a blood clot to the tumor.  Within hours of the clots formation, the tumor begins to die and necrotic regions are formed.  Since every tumor in excess of 2mm in size forms an expanding vascular network during tumor growth, VTA’s could be effective against all types of solid tumors.

IPSCIO Record ID: 2700

License Grant
The two parties entered into a Collaboration Agreement on the development and commercialization of the VEGF Trap in all countries other than Japan, where one party retained the exclusive right to develop and commercialize the VEGF Trap. In January 2005, the parties amended the collaboration Agreement to exclude from the scope of the collaboration the development and commercialization of the VEGF Trap for intraocular delivery to the eye. In December 2005, the parties amended the collaboration Agreement to expand the territory in which the companies are collaborating on the development of the VEGF Trap to include Japan. Under the collaboration Agreement, as amended, the parties will share co-promotion rights and profits on sales, if any, of the VEGF Trap outside of Japan for disease indications included in our collaboration. In Japan, one party is entitled to a royalty on annual sales of the VEGF Trap, subject to certain potential adjustments.
License Property
Under the collaboration Agreement, as amended, agreed upon worldwide development expenses incurred by both companies during the term of the Agreement will be funded by one party. If the collaboration becomes profitable, one party will be obligated to reimburse the other party for 50% of the VEGF Trap development expenses in accordance with a formula based on the amount of development expenses and our share of the collaboration profits and Japan royalties, or at a faster rate at our option.

The VEGF Trap is a protein-based product candidate designed to bind all forms of Vascular Endothelial Growth Factor-A (called VEGF-A, also known as Vascular Permeability Factor or VPF) and the related Placental Growth Factor (called PlGF), and prevent their interaction with cell surface receptors. VEGF-A (and to a less validated degree, PlGF) is required for the growth of new blood vessels that are needed for tumors to grow and is a potent regulator of vascular permeability and leakage.

The VEGF Trap (aflibercept) is being developed in cancer indications in collaboration with another party. We and the other party are preparing to initiate a large Phase 3 program that will evaluate the safety and efficacy of the VEGF Trap in combination with standard chemotherapy regimens in five different cancer types. The first trial is planned to begin in the third quarter of 2007.

Field of Use
The Field of Use apply to the medical industry.

IPSCIO Record ID: 311

License Grant
Licensor hereby grants to each Licensee a non-exclusive, worldwide license under the Licensed Patents for the Term of this Agreement to make, have made, use, offer for sale, sell, import, and export Licensed Product in the Field in the Territory.
License Property
“Licensed Product” shall mean the protein aflibercept, whether sold under the trade name Zaltrap or any other name, and any pharmaceutical formulation of the protein aflibercept with one or more excipients, in each case that is intended for use in the Field in the Territory.
ZALTRAP is an FDA-approved anti-cancer medicine given in combination with a chemotherapy regimen called FOLFIRI (foal-feer-ee) to treat colorectal cancer that has spread.

IP relates to the Davis-Smyth patents, and certain other patents, in all indications for human use other than the prevention or treatment of eye diseases and eye disorders through administration to the eye. Under the terms of the ZALTRAP Agreement, payments are required to be made to licensor based on sales of ZALTRAP in the United States and of ZALTRAP that is manufactured in the United States and sold outside the United States through May 7, 2016.

The partner commenced sales of ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan ('FOLFIRI'), for patients with metastatic colorectal cancer (“mCRC”) that is resistant to or has progressed following an oxaliplatin-containing regimen, in the United States in the third quarter of 2012 and in certain European and other countries in the first quarter of 2013.

The licensee and partner globally collaborate on the development and commercialization of ZALTRAP.

Licensed Patents
.S. Patent No. 5,952,199
U.S. Patent No. 6,100,071
U.S. Patent No. 6,383,486
U.S. Patent No. 6,897,294
U.S. Patent No. 7,771,721
U.S. Patent No. 8,268,313
U.S. Patent No. 8,268,591
U.S. Patent No. 8,273,353
U.S. Patent Application No. 08/643,839
U.S. Patent No. 7,998,931
U.S. Patent No. 8,007,799
U.S. Patent No. 8,287,873
U.S. Patent Application No. 12/002,605

Field of Use
“Field” shall mean and be limited to the prevention or treatment of any disease or condition in a human through the administration of Licensed Product, excluding only the Ocular Field. As used herein, “Ocular Field” shall mean the prevention or treatment of eye diseases and eye disorders in a human through the administration of Licensed Product to the eye (including, but not limited to, the prevention or treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and/or myopic choroidal neovascularization in a human).

IPSCIO Record ID: 227234

License Grant
Licensor hereby grants to Japanese Licensee an exclusive, royalty-bearing license under the Licensor Technology and Licensors interest in the Joint Technology, to make, have made use, sell and otherwise commercialize Collaboration Products for all uses in the Field in the Territory.
License Property
U.S. Patent Application Serial No. 08/745,375 entitled 'Methods for Promoting Wound Healing and Transplant-Assoctaed Vasculopathy'

U.S. Patent Application Serial No. 08/816,346 entitled 'Chimeric Adenoviral Coat Protein and Methods of Using Same'

U.S. Patent Application Serial No. 08/854,601 entitled 'Multigene HSV Vectors for Cancer Immunotherapy'

U.S. Patent Application Serial No. 08/861,773 entitled 'An Improved Method for the Production of Non-Group C Adenoviral Vectors'

U.S. Patent Application Serial No. 60/047,849 entitled 'Alternately Targeted Adenovirus'

U.S. Patent Application Serial No. 60/049,072 entitled 'Phage Vector and Methods of Use'

U.S. Patent Application Serial No. 60/054,329 entitled.'Targeted HSV Vectors'

Field of Use
Field shall mean Gene Therapy for the treatment of human cancer excluding any use of the vascular endothelial growth factor (VEGF) gene or tumor necrosis factor alpha (TNF) gene or, in each case, any portion or derivative thereof.

The collaboration involves the development of Ad.CD for immunotherapy of cancer based on the delivery of tumor antigen genes. Ad.CD, an adenovirus vector containing the cytosine deaminase ('CD') gene, is designed to convert a nontoxic precursor drug into fluorouracil to effect tumor destruction, either alone or in combination with radiation therapy.

IPSCIO Record ID: 227271

License Grant
The University grants to Licensee
– the exclusive worldwide license in the Field of Use to use the Patent to manufacture and sell the Product; and,
– the right to grant sublicenses to any Patent licensed exclusively hereunder, provided that any Sublicensee agrees to be bound by the terms and conditions of this Agreement applicable to Sublicensees.

The agreement is exclusive except for the non-exclusive license granted to the U.S. government

License Property
The patents are for Method and Composition for Angiogenesis Inhibition, Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth, and, Generation And Use Of MABXL313 To Inhibit
Angiogenesis And Tumor Growth In Vivo.

2805 60/114,878 January 6, 1999 Method and Composition for Angiogenesis Inhibition

2806 60/114,877 January 6, 1999 Method and Composition for Angiogenesis Inhibition

2908 60/143,581 July 13, 1999 Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth

2909 60/143,534 July 13, 1999 'Generation And Use Of MAB XL313 To Inhibit Angiogenesis And Tumor Growth In Vivo

Anti-Angiogenesis for the Treatment of Cancer

In a process known as angiogenesis, cancer cells stimulate the formation of new blood vessels in order to bring oxygen and nutrients to rapidly-growing tumor tissue. The onset of angiogenesis is caused mainly by tumor cell production of growth factors that activate the cells that line the blood vessels. These activated cells begin to divide and lead to the remodeling of the extracellular matrix, which is a dense protein network that provides support and growth signals for blood vessels and tumors.

Field of Use
Field of Use shall mean any field of use.

IPSCIO Record ID: 280643

License Grant
The Parties have an agreement to develop technology useful for in vitro and/or in vivo target identification and/or target validation using RNAi and to develop RNAi therapeutic products.

For the RHOA Target, pursuant to the terms of the Original Agreement, Licensor selected the RHOA Target for the development of RNAi Products directed toward such Target (RHOA Products) and Licensee has an opt-in right for further development and commercialization of RHOA Products.

For the royalty bearing products, the Opt-Out Party/Licensor grants the Continuing Party a license under and to Licensor Technology, that is applicable to such Royalty-Bearing Product, to Develop, Manufacture and Commercialize such Royalty-Bearing Product in the Field in the Territory.

For the Profit-Sharing Products
For Development Licenses, Licensor grants a worldwide license in the Territory, with a right to sublicense to its Affiliates, under Licensor Target Identification and Target Validation RNAi Patent Rights, under Licensors interest in Joint Collaboration Patent Rights and Joint Collaboration Inventions, under Licensor Technology Collaboration Inventions, to Licensor RNAi Technology and under Licensor-Assigned Therapeutic Collaboration Inventions, for the sole purpose of in vitro and/or in vivo target identification and/or target validation research relating to drug discovery and/or development activities of Licensee and/or its Affiliates, including in collaborations with Third Parties in which Licensee and/or its Affiliates has any rights to discoveries made.

For Commercialization Licenses,  Licensor grants a license under and to any and all Licensor Technology to Commercialize Profit-Sharing Products in the Field in the Territory.

The foregoing license shall be Exclusive, Co-exclusive or Non-exclusive, depending upon the time period.

License Property
The developed technology will relate to in vitro and/or in vivo target identification and/or target validation using RNAi and to develop RNAi therapeutic products.

Combination Product means a RHOA Product or an RNAi Therapeutic Product combined with any other clinically active ingredient.

Field of Use
The Field shall mean the treatment and/or prophylaxis of diseases in humans with RNAi Therapeutic Products.

RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. RNAi is induced by small, double-stranded RNA molecules. One method to activate RNAi is with chemically synthesized small interfering RNAs, or siRNAs, which are double-stranded RNAs that are targeted to a specific disease-associated gene. The siRNA molecules are used by the natural RNAi machinery in cells to cause highly targeted gene silencing.

Vascular endothelial growth factor (VEGF), originally known as vascular permeability factor (VPF),[1] is a signal protein produced by cells that stimulates the formation of blood vessels.  To be specific, VEGF is a sub-family of growth factors, the platelet-derived growth factor family of cystine-knot growth factors.

IPSCIO Record ID: 344541

License Grant
University grants an exclusive license, with the right to sublicense, to make, have made, use, have used, import, have imported, offer for sale, have offered for sale, have sold and sell the licensed products in the United States and worldwide under the Patent rights in the Licensed Field.
License Property
The license relates to an invention(s) entitled PSMA Targeted Nanoparticles for Therapy of Prostate Cancer. PSMA is a clinically-validated tumor marker expressed on prostate cancer cells and the blood vessels of many types of non-prostate solid tumors.
Field of Use
The Licensed field shall mean all fields.  Licensee is a clinical-stage nanomedicine platform company developing novel targeted and programmable therapeutics.

IPSCIO Record ID: 26536

License Grant
The Licensee announced that the Licensor decided not to exercise its option under the product development and commercialization Agreement between the Licensee and the Licensor to License XL647 for further development and commercialization. The Licensee reported in May 2007 that it had notified the Licensor of it's determination that it had achieved proof-of-concept for XL647 based on data from a phase 2 clinical trial, thereby triggering a 90-day review period in which the Licensor could exercise its option. As a result of the decision by the Licensor not to exercise its option, the Licensee retains the right to develop and commercialize XL647 either independently or in collaboration with third parties.
Field of Use
The Licensee intends to move forward with the full development of XL647 in patients with non-small cell lung cancer and potentially other indications.  XL647 is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). XL647 inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. In addition, XL647 inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. In a broad array of preclinical tumor models including breast, lung, colon and prostate cancer, XL647 demonstrated potent inhibition of tumor growth and causes tumor regression. In cell culture models, XL647 retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.

IPSCIO Record ID: 383584

License Grant
Licensor grants a worldwide exclusive right and license under Know-how, with the right to sublicense others, to make, have made, use, sell, offer for sale and import Licensed Products.

Licensor grants an exclusive license under Patent Rights, with respect to Licensors fifty percent ownership interest in such Patent Rights, with the right to sublicense others, to make, have made, use, sell, offer for sale and import Licensed Products in all jurisdictions outside the United States.

License Property
Licensed Products shall mean Erbitux®, and matuzumab  as well as all derivatives, analogs, fragments, improvements, conjugates and bioequivalents of any of the foregoing.

Erbitux® shall mean cetuximab, and marketed as Erbitux®.

ERBITUX (cetuximab) is an epidermal growth factor receptor (EGFR) inhibitor. EGFR is a receptor found on both normal and tumor cells that is important for cell growth.

The patent is titled Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same.

Field of Use
Erbitux ( cetuximab) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.

IPSCIO Record ID: 33130

License Grant
The Licensor of Hong Kong and Licensee of China agree to collaborate with respect to the Development of the Product in the Field with the goal of obtaining Regulatory Approval for Products in the Field in the Territory for Manufacturing and Commercialization. Lilly will have exclusive rights to Commercialize the Products in the Field in the Territory.

For the Exclusive License and Right to Sublicense, Licensor grants an exclusive license, including the right to grant sublicenses, under Licensor Patents, Know-How and Regulatory Approvals to Develop, use, import and Commercialize, but, for clarity, not to make or have made Products in the Field in the Territory.

License Property
Licensor is the owner of a molecule HMPL-013 and is developing it for the Chinese market as a pharmaceutical product useful in the treatment of cancer.

Product means any form or dosage of the HMPL-013 molecule or any analogues or derivatives of the HMPL-013 molecule that are claimed by those Licensor Patents that also claim HMPL-013, in each case that exist as of the Effective Date or are discovered or developed by Licensor during the Term of this Agreement.

HMPL-013, named  Fruquintinib, patents and patent applications report compounds related to Fruquintinib and compositions comprising at least one compound, and methods for inhibiting KDR activity and treating angiogenesis–related disorders with such compounds/compositions.
Fruquintinib is a selective inhibitor of the Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinases.

Combination Products means any combination or Product and one or more additional active pharmaceutical ingredients, for example in a single delivery device such as a pre-filled pen, dual chamber needle or in a fixed dose combination.

Fruquintinib is a highly selective and potent oral inhibitor of the vascular endothelial growth factor receptor, or VEGFR, and consequently we believe it has the potential to be a global best-in-class VEGFR inhibitor for many types of solid tumors. Based on pre-clinical and clinical data to date, fruquintinibs kinase selectivity has been shown to reduce off-target toxicity. This allows for drug exposure that is able to fully inhibit VEGFR, a protein ligand which contributes to the growth of tumors, and use in potential combinations with other targeted therapies and chemotherapy in earlier lines of treatment with larger patient populations.

Field of Use
Fruquintinib (HMPL-013), is a targeted oncology therapy for the potential treatment of various types of solid tumors.

The Field means all uses.  Initial Indications mean 3rd line colorectal cancer, 3rd line non-small cell lung cancer and 2nd line advanced gastric cancer. Each of the Initial Indications shall be an Initial Indication.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.